Summary

The Acute Lung Injury Treatment Market is steadily evolving as global healthcare systems intensify efforts to address severe respiratory conditions. Acute lung injury (ALI), including acute respiratory distress syndrome (ARDS), continues to present a critical burden due to its complex pathology and high fatality rates. The increasing incidence of respiratory infections, sepsis, trauma, and environmental risk factors has amplified the need for effective therapeutic interventions. Healthcare providers are increasingly focusing on early diagnosis and advanced treatment strategies to improve survival rates and patient outcomes. Continuous advancements in critical care medicine, combined with rising awareness about respiratory health, are contributing to the expansion of this market across developed and developing regions.

Market Insights

The Acute Lung Injury Treatment Market is projected to expand from 3.1 billion in 2026 to 3.9 billion by 2033, reflecting a compound annual growth rate (CAGR) of 3.30% over the forecast period. This growth is supported by increasing demand for intensive care treatments and supportive respiratory therapies. Pharmacological interventions, along with mechanical ventilation and oxygen therapy, remain key components of treatment protocols. Additionally, the adoption of extracorporeal membrane oxygenation (ECMO) is gaining traction in severe cases, enhancing survival rates in critical conditions. The market is also benefiting from innovations in biologics and targeted therapies that aim to reduce inflammation and improve lung function. As clinical research continues to evolve, treatment approaches are becoming more personalized and effective.

Market Drivers

The rising prevalence of respiratory diseases is a major factor driving the Acute Lung Injury Treatment Market. Conditions such as pneumonia, sepsis-induced lung injury, and trauma-related complications are increasing globally, leading to higher demand for advanced treatment solutions. Environmental factors such as air pollution and smoking further exacerbate lung health issues. The aging population is particularly vulnerable to respiratory disorders, contributing significantly to market growth. Additionally, the growing number of hospital admissions in intensive care units has increased the use of ventilators and oxygen support systems. Ongoing research and development activities focused on improving therapeutic outcomes and minimizing adverse effects are also accelerating market expansion.

Business Opportunity

The market offers considerable growth opportunities for pharmaceutical and biotechnology companies. The development of innovative drugs, including anti-inflammatory agents, biologics, and regenerative therapies, is expected to reshape the treatment landscape. Companies investing in stem cell-based therapies and precision medicine approaches are likely to gain a competitive advantage. Furthermore, the increasing demand for advanced respiratory support devices presents opportunities for medical device manufacturers. Emerging economies, particularly in Asia Pacific and Latin America, are creating new avenues for growth due to improving healthcare infrastructure and rising healthcare investments. Strategic partnerships and collaborations are anticipated to drive innovation and expand market reach.

Region Analysis

North America holds a dominant position in the Acute Lung Injury Treatment Market, supported by advanced healthcare infrastructure, high healthcare expenditure, and a strong presence of leading industry players. The region also benefits from extensive research and development activities and favorable reimbursement policies. Europe follows closely, driven by increasing awareness of respiratory diseases and government initiatives to enhance critical care services. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to a large patient population, rising incidence of respiratory conditions, and expanding access to healthcare facilities. Latin America and the Middle East & Africa are gradually emerging as important markets, supported by ongoing investments in healthcare systems and increasing adoption of advanced treatment technologies.

Key Players

• GlaxoSmithKline plc

• Bayer AG

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd.

• Eli Lilly and Company

• Octapharma AG

• Ono Pharmaceutical Co., Ltd.

• Asklepion Pharmaceuticals, LLC

• Edesa Biotech

• Direct Biologics

• Windtree Therapeutics, Inc.

• Apeiron Biologics AG

• ReAlta Life Sciences, Inc.

• Stemedica Cell Technologies, Inc.

• Histocell

Segmentation

By Treatment Type

• Pharmacological Therapy

• Oxygen Therapy

• Mechanical Ventilation

• Extracorporeal Membrane Oxygenation (ECMO)

By Drug Class

• Corticosteroids

• Antibiotics

• Bronchodilators

• Diuretics

• Vasodilators

• Others

By Indication

• Acute Respiratory Distress Syndrome (ARDS)

• Pneumonia-induced Lung Injury

• Sepsis-induced Lung Injury

• Trauma-related Lung Injury

• Others

By Route of Administration

• Intravenous

• Oral

• Inhalation

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

By Geography

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Acute Lung Injury Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Acute Lung Injury Treatment Market Outlook, 2020 - 2033
3.1. Global Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
3.1.1. Pharmacological Therapy
3.1.2. Oxygen Therapy
3.1.3. Mechanical Ventilation
3.1.4. Extracorporeal Membrane Oxygenation (ECMO)
3.2. Global Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
3.2.1. Corticosteroids
3.2.2. Antibiotics
3.2.3. Bronchodilators
3.2.4. Diuretics
3.2.5. Vasodilators
3.2.6. Others
3.3. Global Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
3.3.1. Acute Respiratory Distress Syndrome (ARDS)
3.3.2. Pneumonia-induced Lung Injury
3.3.3. Sepsis-induced Lung Injury
3.3.4. Trauma-related Lung Injury
3.3.5. Others
3.4. Global Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
3.4.1. Intravenous
3.4.2. Oral
3.4.3. Inhalation
3.5. Global Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
3.5.1. Hospital Pharmacies
3.5.2. Retail Pharmacies
3.5.3. Online Pharmacies
3.6. Global Acute Lung Injury Treatment Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.6.1. North America
3.6.2. Europe
3.6.3. Asia Pacific
3.6.4. Latin America
3.6.5. Middle East & Africa
4. North America Acute Lung Injury Treatment Market Outlook, 2020 - 2033
4.1. North America Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
4.1.1. Pharmacological Therapy
4.1.2. Oxygen Therapy
4.1.3. Mechanical Ventilation
4.1.4. Extracorporeal Membrane Oxygenation (ECMO)
4.2. North America Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
4.2.1. Corticosteroids
4.2.2. Antibiotics
4.2.3. Bronchodilators
4.2.4. Diuretics
4.2.5. Vasodilators
4.2.6. Others
4.3. North America Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
4.3.1. Acute Respiratory Distress Syndrome (ARDS)
4.3.2. Pneumonia-induced Lung Injury
4.3.3. Sepsis-induced Lung Injury
4.3.4. Trauma-related Lung Injury
4.3.5. Others
4.4. North America Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
4.4.1. Intravenous
4.4.2. Oral
4.4.3. Inhalation
4.5. North America Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
4.5.1. Hospital Pharmacies
4.5.2. Retail Pharmacies
4.5.3. Online Pharmacies
4.6. North America Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.6.1. U.S. Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
4.6.2. U.S. Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
4.6.3. U.S. Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
4.6.4. U.S. Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
4.6.5. U.S. Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
4.6.6. Canada Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
4.6.7. Canada Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
4.6.8. Canada Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
4.6.9. Canada Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
4.6.10. Canada Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
4.7. BPS Analysis/Market Attractiveness Analysis
5. Europe Acute Lung Injury Treatment Market Outlook, 2020 - 2033
5.1. Europe Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
5.1.1. Pharmacological Therapy
5.1.2. Oxygen Therapy
5.1.3. Mechanical Ventilation
5.1.4. Extracorporeal Membrane Oxygenation (ECMO)
5.2. Europe Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
5.2.1. Corticosteroids
5.2.2. Antibiotics
5.2.3. Bronchodilators
5.2.4. Diuretics
5.2.5. Vasodilators
5.2.6. Others
5.3. Europe Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
5.3.1. Acute Respiratory Distress Syndrome (ARDS)
5.3.2. Pneumonia-induced Lung Injury
5.3.3. Sepsis-induced Lung Injury
5.3.4. Trauma-related Lung Injury
5.3.5. Others
5.4. Europe Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
5.4.1. Intravenous
5.4.2. Oral
5.4.3. Inhalation
5.5. Europe Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
5.5.1. Hospital Pharmacies
5.5.2. Retail Pharmacies
5.5.3. Online Pharmacies
5.6. Europe Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.6.1. Germany Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.2. Germany Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.3. Germany Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.4. Germany Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.5. Germany Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.6.6. Italy Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.7. Italy Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.8. Italy Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.9. Italy Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.10. Italy Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.6.11. France Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.12. France Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.13. France Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.14. France Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.15. France Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.6.16. U.K. Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.17. U.K. Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.18. U.K. Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.19. U.K. Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.20. U.K. Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.6.21. Spain Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.22. Spain Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.23. Spain Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.24. Spain Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.25. Spain Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.6.26. Russia Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.27. Russia Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.28. Russia Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.29. Russia Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.30. Russia Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.6.31. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
5.6.32. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
5.6.33. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
5.6.34. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
5.6.35. Rest of Europe Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
5.7. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Acute Lung Injury Treatment Market Outlook, 2020 - 2033
6.1. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
6.1.1. Pharmacological Therapy
6.1.2. Oxygen Therapy
6.1.3. Mechanical Ventilation
6.1.4. Extracorporeal Membrane Oxygenation (ECMO)
6.2. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
6.2.1. Corticosteroids
6.2.2. Antibiotics
6.2.3. Bronchodilators
6.2.4. Diuretics
6.2.5. Vasodilators
6.2.6. Others
6.3. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
6.3.1. Acute Respiratory Distress Syndrome (ARDS)
6.3.2. Pneumonia-induced Lung Injury
6.3.3. Sepsis-induced Lung Injury
6.3.4. Trauma-related Lung Injury
6.3.5. Others
6.4. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
6.4.1. Intravenous
6.4.2. Oral
6.4.3. Inhalation
6.5. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
6.5.1. Hospital Pharmacies
6.5.2. Retail Pharmacies
6.5.3. Online Pharmacies
6.6. Asia Pacific Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.6.1. China Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
6.6.2. China Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
6.6.3. China Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
6.6.4. China Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
6.6.5. China Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
6.6.6. Japan Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
6.6.7. Japan Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
6.6.8. Japan Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
6.6.9. Japan Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
6.6.10. Japan Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
6.6.11. South Korea Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
6.6.12. South Korea Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
6.6.13. South Korea Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
6.6.14. South Korea Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
6.6.15. South Korea Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
6.6.16. India Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
6.6.17. India Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
6.6.18. India Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
6.6.19. India Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
6.6.20. India Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
6.6.21. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
6.6.22. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
6.6.23. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
6.6.24. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
6.6.25. Southeast Asia Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
6.6.26. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
6.6.27. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
6.6.28. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
6.6.29. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
6.6.30. Rest of SAO Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
6.7. BPS Analysis/Market Attractiveness Analysis
7. Latin America Acute Lung Injury Treatment Market Outlook, 2020 - 2033
7.1. Latin America Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
7.1.1. Pharmacological Therapy
7.1.2. Oxygen Therapy
7.1.3. Mechanical Ventilation
7.1.4. Extracorporeal Membrane Oxygenation (ECMO)
7.2. Latin America Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
7.2.1. Corticosteroids
7.2.2. Antibiotics
7.2.3. Bronchodilators
7.2.4. Diuretics
7.2.5. Vasodilators
7.2.6. Others
7.3. Latin America Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
7.3.1. Acute Respiratory Distress Syndrome (ARDS)
7.3.2. Pneumonia-induced Lung Injury
7.3.3. Sepsis-induced Lung Injury
7.3.4. Trauma-related Lung Injury
7.3.5. Others
7.4. Latin America Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
7.4.1. Intravenous
7.4.2. Oral
7.4.3. Inhalation
7.5. Latin America Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
7.5.1. Hospital Pharmacies
7.5.2. Retail Pharmacies
7.5.3. Online Pharmacies
7.6. Latin America Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.6.1. Brazil Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
7.6.2. Brazil Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
7.6.3. Brazil Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
7.6.4. Brazil Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
7.6.5. Brazil Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
7.6.6. Mexico Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
7.6.7. Mexico Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
7.6.8. Mexico Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
7.6.9. Mexico Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
7.6.10. Mexico Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
7.6.11. Argentina Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
7.6.12. Argentina Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
7.6.13. Argentina Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
7.6.14. Argentina Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
7.6.15. Argentina Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
7.6.16. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
7.6.17. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
7.6.18. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
7.6.19. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
7.6.20. Rest of LATAM Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
7.7. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Acute Lung Injury Treatment Market Outlook, 2020 - 2033
8.1. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2020-2033
8.1.1. Pharmacological Therapy
8.1.2. Oxygen Therapy
8.1.3. Mechanical Ventilation
8.1.4. Extracorporeal Membrane Oxygenation (ECMO)
8.2. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
8.2.1. Corticosteroids
8.2.2. Antibiotics
8.2.3. Bronchodilators
8.2.4. Diuretics
8.2.5. Vasodilators
8.2.6. Others
8.3. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Indication, Value (US$ Bn), 2020-2033
8.3.1. Acute Respiratory Distress Syndrome (ARDS)
8.3.2. Pneumonia-induced Lung Injury
8.3.3. Sepsis-induced Lung Injury
8.3.4. Trauma-related Lung Injury
8.3.5. Others
8.4. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
8.4.1. Intravenous
8.4.2. Oral
8.4.3. Inhalation
8.5. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
8.5.1. Hospital Pharmacies
8.5.2. Retail Pharmacies
8.5.3. Online Pharmacies
8.6. Middle East & Africa Acute Lung Injury Treatment Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.6.1. GCC Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
8.6.2. GCC Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
8.6.3. GCC Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
8.6.4. GCC Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
8.6.5. GCC Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
8.6.6. South Africa Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
8.6.7. South Africa Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
8.6.8. South Africa Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
8.6.9. South Africa Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
8.6.10. South Africa Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
8.6.11. Egypt Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
8.6.12. Egypt Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
8.6.13. Egypt Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
8.6.14. Egypt Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
8.6.15. Egypt Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
8.6.16. Nigeria Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
8.6.17. Nigeria Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
8.6.18. Nigeria Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
8.6.19. Nigeria Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
8.6.20. Nigeria Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
8.6.21. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Treatment Type, 2020-2033
8.6.22. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Drug Class, 2020-2033
8.6.23. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Indication, 2020-2033
8.6.24. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Route of Administration, 2020-2033
8.6.25. Rest of Middle East Acute Lung Injury Treatment Market Outlook, by Distribution Channel, 2020-2033
8.7. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. GlaxoSmithKline plc
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Bayer AG
9.4.3. Pfizer Inc.
9.4.4. Teva Pharmaceutical Industries Ltd.
9.4.5. Eli Lilly and Company
9.4.6. Octapharma AG
9.4.7. Ono Pharmaceutical Co., Ltd.
9.4.8. Asklepion Pharmaceuticals, LLC
9.4.9. Edesa Biotech
9.4.10. Direct Biologics
9.4.11. Windtree Therapeutics, Inc.
9.4.12. Apeiron Biologics AG
9.4.13. ReAlta Life Sciences, Inc.
9.4.14. Stemedica Cell Technologies, Inc.
9.4.15. Histocell
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations